Ovarian Cancer
Conditions
Brief summary
Ovarian cancer is associated with the highest mortality of all gynecologic cancers. In patients with newly diagnosed advanced ovarian cancer after platinum-containing chemotherapy plus bevacizumab therapy, maintenance therapy with olaparib plus bevacizumab significantly prolongs progression-free survival (PFS) in the intended population and is recommended by guidelines. However, study shows those homologous recombinant repair defect (HRD) but Breast Cancer Susceptibility Gene(BRCA) wild type have limited benefit from maintenance therapy with olaparib plus bevacizumab when surgery is with residual(no-R0). Can hyperthermic intraperitoneal chemotherapy(HIPEC) improve the benefits of first-line maintenance therapy in patients with non-R0 resection, HRD? The cohort study will enroll 310 patients with HRD and no-R0 resection who conduct HIPEC during primary treatment and then have olaparib plus bevacizumab as maintenance. Follow-up period is 30 months. The primary endpoint is PFS.
Interventions
PROCEDUREHIPEC
HIPEC is given after primary or interval debulking surgery.
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Inclusion criteria
* Age 18-70 years * Eastern Cooperative Oncology Group (ECOG) score 0-1 * Adequate kidney function (blood creatinine 58-96µmol/L) * Adequate haematological function (haemoglobin ≥110g/L, leucocytes ≥4.0×109/L, neutrophils ≥2.0×109/L, platelets≥100×109/L) * Adequate liver function (serum total bilirubin 3.4-22.2µmol/L, alanine aminotransferase (ALT) 7-40U/L, aspartate aminotransferase (AST) 13-35U/L, AST/ALT ≤1.5 * surgery with residual * eligible to the maintenance therapy of olaparib plus bevacizumab
Exclusion criteria
* Expected life span ≤8 weeks * Complicated with any other known malignancies * Patients with dysfunction of swallow and digestion * Patients who had received any kind of poly adenosinediphosphate-ribose polymerase（PARP）inhibitor * refractory hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS | from the date of recruitment to the time of recurrence, assessed up to 30 months |
Secondary
| Measure | Time frame |
|---|---|
| overall survival | from the date of recruitment to the time of death from any cause, assessed up to 30 months |
| adverse effect | from the date of recruitment up to 30 months |
Countries
China
Contacts
Primary ContactMiao Fang Wu
Outcome results
None listed